Cloprostenol - Administration & dosage
Research News and Information

Sunday, November 22, 2009

Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study.

30 Jul 2009 PURPOSE: To assess the usefulness and tolerability of systematically switching glaucoma patients from latanoprost 0.005% and timolol 0.5% (Lat + Tim) to a fixed combination of travoprost 0.004%/timolol 0.5% (TTFC), and to record the effects of this ... Read more...

Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.

17 Apr 2009 PURPOSE: To identify risk factors for poor adherence to topical once daily therapy for glaucoma. DESIGN: Prospective, observational cohort study. PARTICIPANTS: A total of 196 patients with glaucoma who were being treated with a prostaglandin analog ... Read more...

First-year treatment patterns among new initiators of topical prostaglandin analogs.

30 Mar 2009 OBJECTIVE: To evaluate treatment patterns and costs among new initiators of topical prostaglandin analogs in a managed-care population. RESEARCH DESIGN AND METHODS: Annual costs were modeled using multiple inputs. A retrospective cohort design was ... Read more...

Latest indexed articles for 'Cloprostenol - Administration & dosage'

These are the very latest articles for this heading:

• Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata. 30 Aug 2009
• Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study. 30 Jul 2009
• Relative efficacy of prostaglandins. 29 Jun 2009
• Corneal thickness and glaucoma medications. 29 Jun 2009
• Bimatoprost 0.03% solution (latisse) for eyelash enhancement. 30 May 2009
• Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. 17 Apr 2009
• First-year treatment patterns among new initiators of topical prostaglandin analogs. 30 Mar 2009
• Intraocular pressure control among patients transitioned from latanoprost to travoprost at a Veterans Affairs Medical Center Eye Clinic. 30 Mar 2009
• Safety and effectiveness of topical bimatoprost. 30 Mar 2009
• Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma. 30 Mar 2009
• Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. 30 Mar 2009
• The effect of travoprost 0.004% as an adjuvant to timolol 0.5% therapy. 27 Feb 2009
• Travoprost in children: adverse effects and intraocular pressure response. 30 Jan 2009
• Increased iridial pigmentation in Chinese eyes after use of travoprost 0.004%. 30 Jan 2009
• Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. 30 Jan 2009
• Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. 30 Jan 2009
• Efficiency of estrous synchronization in tropical sheep by combining short-interval cloprostenol-based protocols and "male effect". 27 Jan 2009
• Plasma luteinizing hormone concentrations in cows given repeated treatments or three different doses of gonadotropin releasing hormone. 6 Jan 2009
• [Efficacy of latanoprost versus travoprost assessed by daily intraocular pressure curve] 30 Dec 2008
• [Receptors involved in the mechanism of action of topical prostaglandines] 30 Dec 2008

See a longer list of these articles.

Technical information about 'Cloprostenol'

Definition: A synthetic prostaglandin F2alpha analog. The compound has luteolytic effects and is used for the synchronization of estrus in cattle.

Chemical name: 5-Heptenoic acid, 7-(2-(4-(3-chlorophenoxy)-3-hydroxy-1-butenyl)-3,5-dihydroxycyclopentyl)-, (1alpha(Z),2beta(1E,3R*),3alpha,5alpha)-(+-)-

Registry Number: 40665-92-7

Descriptor UI: D003008

Alternative terms: Cloprostenol; Oestrophan; ICI-80,966; ICI 80,966; ICI80,966; Cloprostenol Sodium; Sodium, Cloprostenol; Cloprostenol Monosodium Salt; Monosodium Salt, Cloprostenol; Salt, Cloprostenol Monosodium; Estrumate;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Luteolytic Agents;

Tree Number: D10.251.355.255.550.700.500.175; D23.469.700.670.175;

History Note: 91(79); was see under PROSTAGLANDINS F, SYNTHETIC 1979-90